The "Administrative Measures for the Implementation or Use of Specific Medical Technology Inspection and Testing Medical Instruments" (hereinafter referred to as the "Special Administrative Measures") has aroused controversy, and legal scholars have criticized the enactment of the Special Administrative Measures as not being rigorous, and there is a suspicion of opening a backdoor for the "regenerative medicine bill". In this regard, the biotech industry has also expressed the view that the Special Administrative Measures are quite strict, and that the benefits to the public outweigh the disadvantages when compared to the previous private sector's cellular system.
Legal scholars have criticized the TMR for its lack of rigor Still needs to be reviewed
The TMR has been open for more than a month and has driven the entire biotech community to invest in immune-cell therapies, and recently there has been a steady stream of news about technology transfers, and international collaborations that have been injecting the cancer industry with a new source of energy, and also bringing new patients to the table. It seems to have injected the cancer treatment industry with a stream of living water and brought new hope to the patients. The newest addition to the lineup is the newest addition to the lineup, the newest addition to the lineup, the newest addition to the lineup, the newest addition to the lineup.
Biotech industry believes that the TTG method has a lot to offer Overhauling the past cellular therapy mess
The biotech industry has a different opinion on this, with some biotech company chairmen believing that the TTG method licenses autologous cells and mesenchymal stem cells for medical treatment with a completely stringent specification, which is controversial, and that there is not much room for improvement. There are not many places that can be disputed. On the contrary, there is no special management method to restrain the private sector from speculating indiscriminately, and there is a chaotic phenomenon that can not be managed by hitting the cells indiscriminately, and once the special management method comes out, the cells have to be moved into the management and it is very strict, which is surely more advantageous than disadvantageous.
The legal profession holds a different opinion and should first understand the current state of healthcare and then talk about the bill
The director of the Institute of Healthcare and Biotechnology Law at the Taipei Medical University, Mr. Li Chongxi, also said that the legislative purpose of the special management approach is to regulate the cellular therapy. The first step in the process is to make sure that you are able to get the most out of your time and money, and that you are able to get the most out of your time and money. In contrast to the past, when the clinic did cellular therapy, the Health Bureau was criticized for opening the back door, so it was not possible to protect the public before the special regulation.
Biotech manufacturers are scrambling to declare a special tube for patients to look through and wait for a hope
Since the special tube law on the road, because of the strict specification, in addition to the cellular laboratory needs to be GTP certified, the physician must also be subjected to a specific cellular therapy course training, after learning enough credits to be able to treat the qualification, non-arbitrary health care institutions and physicians can be implemented, the current situation is still not due to the opening of the special tube law, but the current situation is still not clear. As a result, there are still no cases where cell therapy has been formally implemented due to the opening of the special regulation, and many cancer patients are hopeful that the special regulation will accelerate the trial so that they can receive the treatment as soon as possible.